The Gestational Diabetes Market is evolving as rising awareness encourages more women to undergo screening and receive timely management during pregnancy. The market reached USD 1.99 billion in 2024 and is expected to grow to USD 3.704 billion by 2035, registering a 5.81% CAGR. Increased healthcare expenditure, technological progress, and preventive-care initiatives are contributing to this outlook.

Digital monitoring is becoming an increasingly important part of the care pathway. Continuous glucose monitoring systems can provide ongoing information about glucose levels, while mobile health applications can support tracking and patient engagement. The combination of connected devices and telehealth services is helping create more flexible management models for expectant mothers.

Diagnosis remains a major area of opportunity as healthcare systems seek convenient and reliable screening methods. The Oral Glucose Tolerance Test continues to dominate, while Hemoglobin A1c testing is gaining momentum as a less demanding testing option. Improvements in diagnostic technology can help providers streamline screening and identify patients who require closer monitoring.

Treatment demand is closely connected with lifestyle and metabolic risk factors. Dietary changes lead the treatment segment, supported by nutritional counseling and personalized eating plans, while insulin therapy is projected to grow rapidly. Physical activity and oral medications also form part of the management landscape, creating opportunities for integrated care programs.

Regional growth is led by North America, which accounted for more than 45% of global revenue in 2024, while Europe represented around 30% and Asia-Pacific approximately 20%. Asia-Pacific offers additional opportunities as urbanization, changing lifestyles, and maternal healthcare investment increase. Future growth may increasingly depend on digital platforms, remote monitoring, and personalized treatment support.